Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 1999

View Archived Issues

Targeted Genetics obtains exclusive rights to AAV manufacturing patent

Avax to launch M-Vax in Australia, forms joint venture for AC Vaccine

Lexicon Genetics reports on new drug discovery technology

Phase III data reported for LeukoScan in diagnosis of osteomyelitis

Interim phase I/II data presented for Lu-Tex in age-related macular degeneration

CRC selects water-soluble paclitaxel for phase I trial

FDA reduces warnings on Preven emergency contraceptive kit

Inhale begins patient dosing in phase III trial for inhaled insulin

IL-4 fusion toxin effective in preclinical Kaposi's sarcoma models

Active Biotech commences phase I trial of MS treatment ahead of schedule

Abgenix and Japan Tobacco enter collaboration for ABX-IL-8 development

Angiotensin II blockade as a strategy for preventing renal allograft nephropathy

3M seeks development partner for CFC-free nasal inhaler formulation

Erythromycins patented by Taisho

Selective inhibitors of neuronal NOS prepared and tested at Chugai

Another series of cell adhesion inhibitors acting on VLA-4 and/or alpha4/beta7 integrins from Merck

IL-15 can act as a substitute for IL-2 in the rejection process

Naturally occurring anti-H. pylori substances discovered by Takeda

Teijin patents new vitamin D3 derivatives

NA-22598B1 and B2: novel anticancer compounds produced by Streptomyces

Jak3 tyrosine kinase inhibitor prolongs allograft survival in rat model

The Liposome Company seeks approval for Evacet in the E.U.

Oxazolidinone ring-containing antibiotics in development at AstraZeneca

Abstracts covering pharmacology of AR-C68397AA presented at World Congress on Inflammation

First demonstration of prolonged graft survival with a rationally designed IMPDH inhibitor

TAP Holdings seeks approval of erectile dysfunction treatment

ZD-7349 may represent novel approach to allergic and autoimmune diseases

In vitro resistance profile of AG-1776 differs from other protease inhibitors

Clinical pharmacokinetics and safety of novel sPLA2 inhibitor examined in severe sepsis

Protease inhibitor BMS-232632, a valuable weapon in the war on AIDS

DuPont files NDA for Innohep for treatment and prevention of deep vein thrombosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...